Market Research Reports and Industry Reports

Therapeutic Class Report Overview - Future Of GPR Agonist

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Despite about half a dozen distinct targets having been innovated and introduced in the market for the oral treatment of Type 2 diabetes, ~60% of diabetics still exhibit progressive worsening of glycemic control and ~half of them end up with daily insulin. Increasing epidemiology of Type 2 diabetes due to genetic/lifestyle changes, as well as micro/macrovascular (CV) complication associated with diabetes, demands the researcher to find newer options for treating diabetes which can address other consequences along with HbA1c reduction. Selective PPAR agonists, DGAT1 (diglyceride Acyltransferase 1) inhibitors, GPR (G-protein receptor) agonist, Glucokinase inhibitors are some of the early targets which are in clinical development and have the potential to come into the clinic in the next decade.

Amongst these novel targets, a few candidates from GPR (G-protein couple receptors) agonist are nearing late stage development. Ability to directly modulate insulin and GLP-1 secretion in glucose depended manner is the key trait of this class. Through this, GPR agonist controls hyperglycemia without hypoglycemia, and provides weight loss advantage. Recent publications suggest GPR agonist have complementary action with DPP-IV inhibitors. This report discuss in details about the merits/demerits of developing GPR agonist, pipeline GPR agonist together with sales estimate of key pipeline candidate through 2020 across the world.
N/A

List Of Tables

N/A

List Of Figures

N/A

China Breast Cancer Therapeutics Drugs Market Research Report 2018

The global Breast Cancer Therapeutics Drugs market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at

USD 3400View Report

China Urological Cancer Therapeutics Drugs Market Research Report 2018

The global Urological Cancer Therapeutics Drugs market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at

USD 3400View Report

Therapeutic Class Report Overview : Hepatitis C Virus Infection

The launch of Protease inhibitors (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations

USD 1000View Report

Therapeutic Class Report Overview - Japan Biosimilars

200b worth of biologic products is going off patent by 2015 and this value exceeds ~ 500b if we include products that will see their patent expiries by 2021 in

USD 1000View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 1000
  • Site Licence    USD 2000
  • Enterprisewide Licence    USD 3000
$ 1000

Reports Details

Published Date : Feb 2013
No. of Pages :20
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 
istanbul escort istanbul escort istanbul escort izmit escort eskisehir escort samsun escort bursa escort ankara escort konya escort adana escort gaziantep escort kayseri escort izmir escort hatay escort

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube
maltepe escort kartal escort manavgat escort alanya escort konya escort tuzla escort pendik escort maltepe escort maltepe escort